December 16, 2016 / 2:44 PM / 8 months ago

BRIEF-TG Therapeutics says mid-stage data published in the British Journal of Haematology

Dec 16 (Reuters) - TG Therapeutics Inc:

* TG Therapeutics Inc announces publication of clinical data from the phase 2 trial of TG-1101 (ublituximab) in combination with ibrutinib in the british journal of haematology

* An 88% overall response rate was reported at month 6 for all patients treated in phase 2 study of tg-1101

* Phase 2 study of tg-1101 data demonstrates combination to be well tolerated with limited grade 3/4 adverse events observed

* TG Therapeutics- "recently announced completion of enrollment in revised genuine trial and look forward to announcing top line data in first half of 2017" Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below